DDInter1938 DDInter1293
Vincristine is a vinca alkaloid with formula C46H56N4O10 found in the Madagascar periwinkle, Catharanthus roseus. It is used (commonly as the corresponding sulfate salt)as a chemotherapy drug for the treatment of leukaemia, lymphoma, myeloma, breast cancer and head and neck cancer. It has a role as a tubulin modulator, a microtubule-destabilising agent, a plant metabolite, an antineoplastic agent and a drug. It is a methyl ester, an acetate ester, a tertiary alcohol, a member of formamides, an organic heteropentacyclic compound, an organic heterotetracyclic compound, a tertiary amino compound and a vinca alkaloid. It is a conjugate base of a vincristine(2+). It derives from a hydride of a vincaleukoblastine.
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML.
Vincristine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Nilotinib
Vincristine {u} (Compound) upregulates {v} (Gene) CDC42BPB
CDC42BPB {u} (Gene) is bound by {v} (Compound) Nilotinib
Vincristine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Nilotinib
Vincristine {u} (Compound) upregulates {v} (Gene) IKZF1
IKZF1 {u} (Gene) is upregulated by {v} (Compound) Nilotinib
Vincristine {u} (Compound) downregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) is upregulated by {v} (Compound) Nilotinib
Vincristine {u} (Compound) downregulates {v} (Gene) POLR2I
POLR2I {u} (Gene) is downregulated by {v} (Compound) Nilotinib
Vincristine {u} (Compound) upregulates {v} (Gene) CCNB1
CCNB1 {u} (Gene) is downregulated by {v} (Compound) Nilotinib
Vincristine {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Nilotinib
Vincristine {u} (Compound) resembles {v} (Compound) Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Vincristine {u} (Compound) resembles {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Vincristine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Nilotinib (Compound)
Vincristine (Compound) upregulates CDC42BPB (Gene) and CDC42BPB (Gene) is bound by Nilotinib (Compound)
Vincristine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Nilotinib (Compound)
Vincristine (Compound) upregulates IKZF1 (Gene) and IKZF1 (Gene) is upregulated by Nilotinib (Compound)
Vincristine (Compound) downregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Nilotinib (Compound)
Vincristine (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Nilotinib (Compound)
Vincristine (Compound) upregulates CCNB1 (Gene) and CCNB1 (Gene) is downregulated by Nilotinib (Compound)
Vincristine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Nilotinib (Compound)
Vincristine (Compound) resembles Vinorelbine (Compound) and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Vincristine (Compound) resembles Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib